Abstract
Coadministration of nevirapine-based antiretroviral therapy (ART) and artemether-lumefantrine is reported to result in variable changes in lumefantrine exposure. We conducted an intensive pharmacokinetic study with 11 HIV-infected adults who were receiving artemether-lumefantrine plus nevirapine-based ART, and we compared the results with those for 16 HIV-negative adult historical controls. Exposure to artemether and lumefantrine was significantly lower and dihydroartemisinin exposure was unchanged in subjects receiving nevirapine-based ART, compared with controls. Nevirapine exposure was unchanged before and after artemether-lumefantrine administration.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 7852-7856 |
| Number of pages | 5 |
| Journal | Antimicrobial agents and chemotherapy |
| Volume | 59 |
| Issue number | 12 |
| DOIs | |
| State | Published - Dec 1 2015 |
Funding
This work was supported by the National Institutes of Health through the John E. Fogarty International Center (awards 1D43TW007995 and 1D43TW007991) and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (award R01HD068174). Additional support was provided by the Centre for Population and Reproductive Health, College of Medicine, University of Ibadan, with funds from the Gates Institute, Johns Hopkins University School of Public Health. We do not have any conflicts of interest related to this work to report. Mathew Olatunde, N. K. Afolabi, and the entire laboratory and nursing staff of the Department of Clinical Pharmacology, University College Hospital (Ibadan, Nigeria), are appreciated for their dedication. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
ASJC Scopus subject areas
- Pharmacology (medical)
- Infectious Diseases
- Pharmacology
